Presentation is loading. Please wait.

Presentation is loading. Please wait.

V2 vs. V3 product positioning. V2 Situational Analysis Version 2 (V2) of the HL7 standard used in over 90% of American hospitals Other countries such.

Similar presentations


Presentation on theme: "V2 vs. V3 product positioning. V2 Situational Analysis Version 2 (V2) of the HL7 standard used in over 90% of American hospitals Other countries such."— Presentation transcript:

1 V2 vs. V3 product positioning

2 V2 Situational Analysis Version 2 (V2) of the HL7 standard used in over 90% of American hospitals Other countries such as Australia, Canada, Germany, the UK, the Netherlands and Japan (and very likely others) Not just an issue for a very limited number of realms – especially if weighed by existing market size for H-IT products

3 V3 Situational Analysis Used and necessary especially in the context of community, regional and national health information network initiatives such as NHS Connecting for Health (UK), Health InfoWay (Canada), various European and Asian countries, and many others. Multi stakeholder environments/Crossing organizational boundaries (Potential) Standard of choice in –Green-field environments –Realms with centralized decision making bodies

4 V2 vs. V3 Situational Analysis V3 not really V2++ –Entirely different paradigm No straightforward transition path –ROI for upgrade not obvious –Mappings and co-existence possible, and often necessary, but not trivial

5 Branding Choices ApproachV2 = Enterprise Edition V3 = RHIO Edition V2 = (Legacy) Enterprise Edition V3 = Extended Enterprise Edition (Enterprise + RHIO) ProsReflects current legacy situation and suitability of V2 Reflects strength for V3 Does not drop V2 issue of legacy and support Establishes V3 as the standard of the future ConsCould potentially lead to the creation of more V2 legacy in the enterprise. HL7 internal opposition to position V2 as legacy (?).

6 Brand -Name vs. -Association Option 1 (Change Brand Name): –From HL7 V2 to HL7 Enterprise Edition –From HL7 V3 to HL7 Extended Enterprise Edition –Problem: Significant name recognition for V2 and V3. May result a lot in additional confusion in the marketplace Option 2 (Change Brand Association): –V2: Originally designed of the requirements of a single enterprise. HL7s claim to fame. The legacy work-horse for many early adopters of HC information exchange within the context of a single enterprise. Now superseded by the next generation V3. –V3: Designed for a broad spectrum of requirements. The only internationally accepted, industry strength, standard to achieve interoperability within and across the HC enterprise. The foundational standard of choice for regional, national and trans- national exchange of health information.

7 V2 to V3 positioning strategy Migration of existing V2 legacy unlikely to happen rapidly due to cost and unclear ROI –Dont try to push it. It is a waste of energy –Let natural system upgrade cycles take care of it –Sooner or later cost of legacy support will be higher than cost of upgrade Focus on adoption of V3 in green field environments (esp. emerging economies) and for regional, national and trans-national health information networks –Adoption of V3 in RHIO type environments will create pressure towards transition from V2 to V3 to have a coherent V3 end-to-end environment rather than more costly V2/V3 mixed environments

8 V2 to V3 positioning strategy (Articulate in Whitepaper) Single Enterprise V2 Yesterday An Enterprise – HC Service Provider (Hospital, Clinic, Physician) Its business partners (Payers etc.)

9 V2 to V3 positioning strategy (Articulate in Whitepaper) Single Enterprise V3 V2 Single Enterprise V2 Single Enterprise V2 V3 V2 V3 Today for legacy Environments (degree of V3 adoption varies between deployments)

10 V2 to V3 positioning strategy (Articulate in Whitepaper) Single Enterprise V3 Single Enterprise V3 Single Enterprise V3 Today for Green field And transition Target for legacy

11 V2 to V3 transition strategy (Articulate in Whitepaper) No more than 4-5 pages. Well not talk about the RIM, well not talk about semantic interoperability. We focus on what it does for you – not how it does it. HL7 in a fortune cookie. Section 1: Healthcare and Interoperability Standards (Intro) Section 2: HL7 V2.0 – the original HL7 success story. Position V2.0 as success for early movers way back when, but also as legacy pointing out its short-comings for the 21 st century (i.e. HL7 is response to the marketplace and its requirements) Section 3: HL7 V3.0 (Intro) - The only internationally accepted, industry strength, standard to achieve interoperability within and across the HC enterprise. The foundational standard of choice for regional, national and trans-national exchange of health information. Section 4: V2.0 and V3.0 mixed environments. How some countries tackle it (e.g. UK, Germany). It is not easy, but it can be done (because it has to be done). Section 5: V3.0 – the standard of the future. Speak especially to the issues of emerging countries and regional networks. Section 6: Short summary (V2 was as success and will be around for some time to come, V3 is the next generation).

12 Branding: In Summary HL7 V2.0 –An HL7 success story. –Success for early movers, delivered results and has shown the way. –Important existing work-horse on which real-world deployments are based HL7 V3.0 –Designed for the 21st century (i.e. HL7 is responsive to the marketplace and its requirements) –The only internationally accepted, industry strength, standard to achieve interoperability within and across the HC enterprise. –The foundational standard of choice for regional, national and trans-national exchange of health information.


Download ppt "V2 vs. V3 product positioning. V2 Situational Analysis Version 2 (V2) of the HL7 standard used in over 90% of American hospitals Other countries such."

Similar presentations


Ads by Google